目的：讨论康柏西普治疗息肉样脉络膜视网膜病变(PCV)的效果及对患者血液流变学的影响。

方法：选择2017-01/2018-04我院眼科收治PCV患者62例，按照治疗方式差异分成两组，每组31例； 对照组采用雷珠单抗治疗，观察组接受康柏西普治疗； 比较两组眼压、BCVA、黄斑中心凹厚度(CMT)、黄斑中心凹下脉络膜厚度(SFCT)、血液流变学变化、并发症发生情况。

结果：治疗前两组患者眼压、BCVA、CMT、SFCT均无差异(P>0.05)； 随着时间增加，两组患者BCVA升高，CMT、SFCT均降低(P<0.05)； 两组患者BCVA、CMT、SFCT均有差异(P<0.05)； 治疗前后不同时间两组患者眼压均无差异(P>0.05)。观察组全血高切黏度、全血低切黏度、血浆黏度、红细胞聚集指数均低于治疗前且低于对照组(P<0.05)，红细胞变形指数高于治疗前且高于对照组(P<0.05)； 两组患者并发症发生率无差异(3% vs 6%，P>0.05)。

结论：康柏西普应用于PCV可更提高患者视力，改善血液流变，减轻黄斑水肿等临床症状，且其安全性高，对眼压无影响。

METHODS: From January 2017 to April 2018, 62 patients with PCV were enrolled in our hospital. According to the difference of treatment, the patients were divided into two groups, 31 cases in each group. The control group was treated with rapunzumab and the observation group with conbercept. Intraocular pressure, BCVA, CMT, SFCT, hemorheology and complications were compared between the two groups.

RESULTS: There was no difference in intraocular pressure, BCVA, CMT and SFCT between the two groups before treatment(P>0.05). With the increase of time, BCVA increased, CMT and SFCT decreased in both groups(P<0.05). BCVA, CMT and SFCT were different between the two groups(P<0.05). There was no difference in intraocular pressure between the two groups before and after treatment(P>0.05). The whole blood high shear viscosity, whole blood low shear viscosity, plasma viscosity and RBC aggregation index in the observation group were lower than those before treatment and lower than those in the control group(P<0.05), and the RBC deformation index was higher than that before treatment and higher than that in the control group(P<0.05). There was no difference in the incidence of complications between the two groups(3% vs 6%, P>0.05).

CONCLUSION: The application of conbercept in PCV can improve the visual acuity, and have a good impact in the hemorheology, reduce the macular edema and other clinical symptoms, and it has high safety and no effect on intraocular pressure.